

UC Irvine

UC Irvine Previously Published Works

Title

The Herpes Simplex Virus Type 1 Latency-Associated Transcript Inhibits Phenotypic and Functional Maturation of Dendritic Cells

Permalink

<https://escholarship.org/uc/item/6dm509hr>

Journal

Viral Immunology, 25(3)

ISSN

0882-8245

Authors

Chentoufi, Aziz Alami
Dervillez, Xavier
Dasgupta, Gargi
[et al.](#)

Publication Date

2012-06-01

DOI

10.1089/vim.2011.0091

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

The Herpes Simplex Virus Type 1 Latency-Associated Transcript Inhibits Phenotypic and Functional Maturation of Dendritic Cells

Aziz Alami Chentoufi,¹ Xavier Dervillez,¹ Gargi Dasgupta,¹ Chelsea Nguyen,¹ Khaled W. Kabbara,¹ Xianzhi Jiang,² Anthony B. Nesburn,^{1,2} Steven L. Wechsler,^{1,2} and Lbachir BenMohamed³

Abstract

We recently found that the herpes simplex virus-1 (HSV-1) latency-associated transcript (LAT) results in exhaustion of virus-specific CD8⁺ T cells in latently-infected trigeminal ganglia (TG). In this study we sought to determine if this impairment may involve LAT directly and/or indirectly interfering with DC maturation. We found that a small number of HSV-1 antigen-positive DCs are present in the TG of latently-infected CD11c/eYFP mice; however, this does not imply that these DCs are acutely or latently infected. Some CD8⁺ T cells are adjacent to DCs, suggesting possible interactions. It has previously been shown that wild-type HSV-1 interferes with DC maturation. Here we show for the first time that this is associated with LAT expression, since compared to LAT⁽⁻⁾ virus: (1) LAT⁽⁺⁾ virus interfered with expression of MHC class I and the co-stimulatory molecules CD80 and CD86 on the surface of DCs; (2) LAT⁽⁺⁾ virus impaired DC production of the proinflammatory cytokines IL-6, IL-12, and TNF- α ; and (3) DCs infected *in vitro* with LAT⁽⁺⁾ virus had significantly reduced the ability to stimulate HSV-specific CD8⁺ T cells. While a similar number of DCs was found in LAT⁽⁺⁾ and LAT⁽⁻⁾ latently-infected TG of CD11c/eYFP transgenic mice, more HSV-1 Ag-positive DCs and more exhausted CD8 T cells were seen with LAT⁽⁺⁾ virus. Consistent with these findings, HSV-specific cytotoxic CD8⁺ T cells in the TG of mice latently-infected with LAT⁽⁺⁾ virus produced less IFN- γ and TNF- α than those from TG of LAT⁽⁻⁾-infected mice. Together, these results suggest a novel immune-evasion mechanism whereby the HSV-1 LAT increases the number of HSV-1 Ag-positive DCs in latently-infected TG, and interferes with DC phenotypic and functional maturation. The effect of LAT on TG-resident DCs may contribute to the reduced function of HSV-specific CD8⁺ T cells in the TG of mice latently infected with LAT⁽⁺⁾ virus.

Introduction

HERPES SIMPLEX VIRUS TYPE 1 (HSV-1) IS A UBIQUITOUS PATHOGEN that is representative of the alpha-herpesvirus family. Approximately 90% of the human population is seropositive for this virus (1–4). Although HSV-1 usually causes mild lesions on the lips (cold sores), it also causes blinding infection in eyes and fatal encephalitis in the brain (1,2,5–9). After primary infection, HSV-1 persists lifelong in the infected host in the sensory neurons of the trigeminal ganglia (TG) in a non-reproductive, latent state. In this latent form, viral gene expression is limited and immune detection and clearance is thus avoided (1,2,10–13). HSV-specific CD8⁺ T cells in the TG appear to be involved in controlling or reducing spontaneous reactivation of latent virus (1,2,14,15). Among the central is-

issues in the immunobiology of HSV-1 is its apparent ability to evade CD8⁺ T-cell immunosurveillance, and periodically reactivate from latently-infected sensory neurons (1,2,15–18). The HSV-1 latency-associated transcript (LAT) gene, the only viral gene abundantly transcribed during latent infection, promotes survival of infected sensory neurons by reducing apoptosis, thus keeping the virus in the immune sanctuary of neurons (19). Several lines of evidence indicate that LAT functions as an immune evasion gene (1,2). We previously showed that: (1) LAT interferes with and/or delays interferon- γ (IFN- γ) production (20); (2) LAT protects against granzyme B (GrB)-mediated cytotoxic CD8⁺ T-cell killing of neurons (8); and (3) LAT partially reduces CD8⁺ T-cell function in the TG of mice latently infected with HSV-1 by promoting CD8⁺ T-cell exhaustion (1,2). We

¹Laboratory of Cellular and Molecular Immunology, ²Virology Research, The Gavin Herbert Eye Institute, and ³Institute for Immunology, School of Medicine, University of California–Irvine, Irvine, California.

hypothesize that LAT may have an additional immune evasion mechanism, namely interfering with dendritic cell (DC) maturation.

DCs are powerful sentinels in innate and adaptive immunity, due to their unique and critical role in priming (initial activation) of naïve T cells and recall of antiviral memory T-cell responses (21–27). The maturation status of DCs determines whether they induce or tolerize CD8⁺ T cells (28). DCs would therefore be the most crucial and potent antigen-presenting cells (APC) in presenting CD8⁺ T-cell epitopes during the early course of virus reactivation to stimulate TG-resident memory CD8⁺ T cells. CD8⁺ T-cell numbers and their ability to reduce virus replication in the TG are increased in CD11c^{-/-} deficient mice (29). It is well known that *in vitro* HSV-1 can efficiently infect DCs in their immature state, and interfere with their phenotypic maturation (3,26,30–32). This could represent an immune-evasion mechanism that helps HSV-1 escape the host's CD8⁺ T-cell immune surveillance. However, the HSV genes involved in downregulating DC functions are unknown. As LAT is the only HSV-1 gene abundantly transcribed during latency, it is a candidate for modulating DC Ag-presenting function during latent infection (33–35). We hypothesize that LAT inhibits phenotypic maturation of DCs, and subsequently impairs their function of stimulating TG-resident CD8⁺ T cells. This proposed LAT function might be one of the mechanisms involved in increased reactivation of LAT⁽⁺⁾ versus LAT⁽⁻⁾ virus in latently infected TG.

The results reported here strongly suggest that *in vitro* the HSV-1 LAT: (1) reduces DC proinflammatory cytokine production; (2) interferes with cell surface expression of MHC-I and the co-stimulatory molecules CD80 and CD86; and (3) reduces the ability of HSV-1-infected immature DCs to stimulate HSV-specific CD8⁺ T cells. *In vivo*, the data show that mouse TG latently infected with LAT⁽⁺⁾ virus have more HSV-1 Ag-positive DCs, and more exhausted HSV-specific cytotoxic CD8⁺ T cells, despite a similar number of DCs in both LAT⁽⁺⁾ and LAT⁽⁻⁾ TG. To our knowledge, this is the first study to demonstrate that the HSV-1 LAT directly or indirectly abrogates phenotypic and functional maturation of DCs. This may constitute an additional immune evasion mechanism, which helps HSV-1 to escape the immunosurveillance by TG-resident CD8⁺ T cells.

Materials and Methods

CD11c/eYFP transgenic mice

CD11c/eYFP transgenic mice originally developed by Dr. Michel C Nussensweig (Rockefeller University) were kindly provided to us by Dr. James T. Rosenbaum (Oregon Health & Science University). CD11c/eYFP transgenic mice have been successfully used for *in vivo* tracking of activated DCs (36,37). C57BL/6 (B6) mice, 5 wk old, were purchased from the Jackson Laboratory (Bar Harbor, ME). The animal studies conformed to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH). The mice were maintained in air-filtered cages and fed normal mouse chow in the University of California–Irvine (UCI) Animal Care Facility. The UCI Committee on Animal Research approved all procedures (ID #2002-2372).

Virus titration

Plaque-purified HSV-1 strain McKrae (wild-type), and its derived mutants dLAT2903 LAT⁽⁻⁾ and dLAT2903R LAT⁽⁺⁾ were grown in rabbit skin (RS) cell monolayers in minimal essential medium (MEM) containing 5% fetal calf serum (FCS), as described previously (20).

Ocular infection

Mice were infected ocularly without scarification with 2×10^5 pfu of either LAT⁽⁺⁾ or LAT⁽⁻⁾ virus. All viruses were suspended in 5 μ L of tissue culture media and administered as an eye drop. Mock-infected mice received sterile tissue culture media.

Preparation of single-cell suspensions from mouse TG

Mice were euthanized and TG were harvested, pooled, and digested in DMEM-5% FBS containing collagenase I (Life Technologies, Carlsbad, CA), as we previously described (5–8,38). The digested tissue suspension was passed through a 45-mm nylon cell strainer. Cell suspensions were spun down at 1400 rpm for 5 min at 4°C, washed, and suspended in FACS buffer (PBS-0.01%, NaN₃-0.1%, BSA, and 2 mM EDTA) for FACS acquisition and analysis. Ten TG were pooled and digested with collagenase type I. To obtain the number of cells per TG, the total numbers of cells obtained from each 10-TG cell suspension were divided by 10. The cells were stained with mAbs and tetramers, as described below. The lymphocyte populations in the TG suspension were gated from other non-lymphocyte cells (i.e., glial cells, Schwann cells, neurons, and fibroblasts) based on their specific size and granularity. The total number of CD8⁺ T cells was calculated based on the number of gated lymphocytes and used for normalization.

Tetramer assay

TG cell suspensions were analyzed for the frequency of CD8⁺ T cells specific to the HSV-gB_{498–505} epitope using the HSV-gB_{498–505} tetramer, which is H2-K^b-restricted, as we previously described (39). The cells were first incubated with 2 μ L of PE-labeled HSV-gB_{498–505}/H2-K^b tetramer at 4°C for 30–45 min. The cells were washed twice and stained with 1 μ L FITC-conjugated rat anti-mouse CD8 antibody (clone 53-6.7; eBioscience, San Diego, CA). After two additional washings, the cells were fixed with 1% formaldehyde in PBS. A total of 400,000 events were acquired by FACScan (Becton Dickinson, San Jose, CA), followed by analysis using Cell Quest software (BD Biosciences, San Jose, CA). The absolute numbers of HSV-gB_{498–505}-specific CD8⁺ T cells were calculated using the following formula: (N^{br} of CD8⁺ tetramer⁺ cells in the test) – (N^{br} of CD8⁺ tetramer⁺ cells in the negative control). The anti-mouse CD8 mAb was pre-tested prior to use to confirm that it did not interfere with or alter tetramer binding.

CD107 cytotoxicity assay

The CD107 assay was performed as recently described (5–10,40), with a few modifications. Freshly isolated TG-derived cells were left unstimulated, or were stimulated with gB_{498–505} or PHA (positive control) at 37°C for 5–6 h in the

presence of BD GolgiStop (BD Biosciences) and 10 μ L of FITC-conjugated CD107 antibody. The cells were washed and stained with 2 μ L of PE-labeled HSV-gB_{498–505}/H2-K^b tetramer, and 1 μ L of PerCP-conjugated anti-mouse CD8 for 30 min at 4°C. The cells were then washed again and analyzed using a FACScan (BD Biosciences).

Cytokine assay

Dendritic cells were cultured in 6-well plates at 5×10^6 cells/well in CM infected with HSV-1 at MOI 0.3, or incubated with LPS at 0.5 μ g/mL as positive control. The supernatant was harvested from infected DCs every 6 h for 36 h after infection and/or LPS stimulation, and the concentrations of IFN- γ , tumor necrosis factor- α (TNF- α), and IL-12 cytokines were determined using sandwich ELISA kits specific for each cytokine, according to the manufacturer's instructions (BD Pharmingen, San Diego, CA).

Immunohistochemistry

Immunostaining of latently-infected TG was performed on day 35, as we previously described (5,6,7,8,20). Briefly, the mice were euthanized, and TG were harvested, embedded in embedding compound, and snap-frozen. Approximately 10- μ m-thick cryosections were made, fixed in acetone (10 min at room temperature), air-dried, and stored at -80°C. For immunostaining, TG sections were rehydrated in PBS (10 min at room temperature), Fc blocked, and then stained with a rabbit antibody to HSV-1 (catalog no. F031802; Dako, Carpinteria, CA), followed by an anti-rabbit IgG-conjugated with bright orange fluorescent Alexa-Fluor 546 dye (which is spectrally similar to Cy3 dye)-labeled rat anti-HSV-1 antibody (catalog no. A-11071; Molecular Probes, Eugene, OR), at 1:100 dilution in PBS-1% BSA at 4°C overnight. After three successive washings in PBS (3 \times 5 min), the sections were stained with 14.3 mM 4,6-diamino-2-phenylindole (DAPI; Molecular Probes) for 2 min at room temperature to stain cell nuclei. Excess DAPI was removed by washing with PBS (3 \times 5 min), and the slides were mounted in 50% glycerol-PBS and analyzed by fluorescence microscopy.

DNA extraction and real-time PCR analysis

DNA was isolated from individual TG using the commercially available DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA), according to the manufacturer's instructions. For real-time PCR assays, 100 ng of DNA from all samples was subjected to PCR using HSV-1 gB-specific primers. The following primers were used for HSV-1 gB: forward: 5'-AACGCGACGCA CATCAAG-3'; reverse: 5'-CTGGTACG CGA TCAGAAAGC-3'. The amplicon length for this primer set is 72 bp. The primer concentration was 200 nM for both strands. SYBR green master mix (Applied Biosystems, Foster City, CA) was used in a final volume of 25 μ L. Cycling parameters were 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C for 25 sec, and 60°C for 60 sec. The plates were read after each cycle, and a melting curve was generated after amplification using an MJ Research Opticon thermal cycler. PCR controls without reverse transcriptase (water control), or with mock-infected mouse TG genomic DNA, were routinely negative. For relative copy numbers of gB DNA in mice TG, the obtained CT was translated into the

number of copies using standard curves generated from titrated HSV-1 viral DNA.

Generation of bone marrow-derived dendritic cells

Bone marrow-derived DCs were generated from B6 mice, as we previously described (41,42). Briefly, single-cell suspensions of bone marrow cells were cultured in 100-mm Petri dishes at an initial density of 2×10^5 cells/mL in a final volume of 10 mL RPMI-1640 medium supplemented with 50 ng/mL murine GM-CSF and 50 ng/mL IL-4 (PeproTech Inc., Rocky Hill, NJ). After 8–10 days, over 90% of the non-adherent cells had acquired typical dendritic morphology and were at an immature stage. The immature CD11c⁺/CD11b⁺ DCs express low levels of MHC, co-stimulatory, and adhesion molecules. Routinely $\sim 6 \times 10^7$ cells are obtained from one mouse. Differentiation of bone-marrow cells into DCs, which contain a mixture of both plasmacytoid DC and myeloid DC subsets (41,42), was followed by flow cytometry analysis of different surface markers.

DC-CD8⁺ T-cell assay

Immature DCs derived from bone marrow of C57BL/6 mice as described above were infected *in vitro* for 4 h with wild-type McKrae (LAT⁺) or *d*LAT2903 (LAT⁻; MOI=3), and then stimulated for 16 additional hours with 0.5 μ g/mL LPS to induce maturation. The cells were then washed and treated with mitomycin C, and the indicated increased numbers of DCs were incubated in duplicate for 72 h with a constant number (10^5) of autologous CD8⁺ T cells derived from wild-type McKrae-infected C57BL/6 mice. The number of HSV-specific CD8⁺ T cells producing IFN- γ was determined by an ELISpot assay, as we previously described (43).

Statistical analysis

The statistical module Prism was used to perform unpaired two-tailed Student's *t*-tests and analysis of variance (ANOVA) with Tukey's *t*-test. All error bars represent the standard errors of the means. A *p* value <0.05 was considered significant.

Results

More HSV-1 Ag-positive DCs in the TG of CD11c/eYFP transgenic mice latently-infected with LAT⁺ virus compared to LAT⁻ virus

CD11c/eYFP transgenic mice have been recently used for *in vivo* tracking of CNS-resident DCs (36,37). Two groups of CD11c/eYFP transgenic mice (*n*=10) were infected ocularly with: (1) the LAT⁻ mutant *d*LAT2903; or (2) the parental wild-type McKrae. Thirty-five days post-infection (when latency was fully established), the TG were harvested, and (1) the presence of TG-resident HSV Ag-positive CD11c⁺ DCs was detected by confocal microscopy, (2) the number of DCs per TG was determined by FACS, and (3) the amount of viral DNA was determined by qRT-PCR. A small number of HSV-antigen-positive DCs were detected in the TG of CD11c/eYFP transgenic mice latently-infected with LAT⁺ HSV-1 (Fig. 1A). Some CD11c⁺ DCs appeared to be co-localized or adjacent to CD8⁺ cells in the TG of both LAT⁺- (Fig. 1B) and LAT⁻-virus infected mice, suggesting that an *in vivo*




FIG. 1. A small number of HSV-Ag-positive dendritic cells are detected in the TG of CD11c/eYFP transgenic mice latently infected with LAT⁽⁺⁾ virus. TG from CD11c/eYFP transgenic mice latently infected with either LAT⁽⁺⁾ (wild-type McKrae), or LAT⁽⁻⁾ null mutant (*dLAT2903*) virus were removed 35 d post-ocular infection, fixed, embedded in embedding compound, immunostained as indicated, and examined by confocal microscopy, as described in the materials and methods section. All images were captured as grey scale and pseudocolored. YFP channel is shown as green. PE and Cy5 channels are shown as red. DAPI is blue. (A) An HSV-1 antigen-positive DC in the TG of an CD11c/eYFP transgenic mouse latently infected with LAT⁽⁺⁾ HSV-1. Left panel: DC from an eYFP-CD11c transgenic mouse. Center panel: HSV-1 Ag stained with polyclonal Abs. Right panel: Merged image of left and center panels. (B) Some CD8⁺ T-cells (red) appear to co-localize with DCs (green) in the TG from a mouse latently infected with LAT⁽⁺⁾ virus. Arrows point to CD8⁺ T cells. Dotted lines indicate eYFP-CD11c DCs. (C) The average number of total CD11c⁺ DCs detected by FACS in LAT⁽⁺⁾ versus LAT⁽⁻⁾ TG. (D) The average number of HSV-1 antigen-positive DCs detected by FACS in LAT⁽⁺⁾ versus LAT⁽⁻⁾ TG. (E) Latently-infected LAT⁽⁺⁾ TG contained more viral DNA than LAT⁽⁻⁾ TG. The relative copy number of the HSV-1 gB gene was determined in individual TG by RT-PCR, as described in the materials and methods section. All the results are representative of 5 independent experiments from the left and right TG harvested from each mouse 35 d post-infection (10 mice; **p* < 0.05 by ANOVA testing). Color images available online at www.liebertonline.com/vim

DC-CD8 interaction may be occurring in latently-infected TG. Similar numbers of CD11c⁺ DCs were detected in the TG of CD11c/eYFP transgenic mice 35 d post-infection with either LAT⁽⁺⁾ or LAT⁽⁻⁾ virus (Fig. 1C; FACS). The bar graph in Fig. 1D shows that the average number of HSV-1 antigen-positive DCs detected by FACS in a pool of LAT⁽⁺⁾ TG was 15, compared to just 6 in LAT⁽⁻⁾ TG. Consistent with previous studies (44,45), more HSV-1 DNA was detected in LAT⁽⁺⁾-infected TG compared to LAT⁽⁻⁾-infected TG (Fig. 1E).

Because of the low number of DCs/TG (an average of 15 DCs/LAT⁽⁺⁾ TG and 6 DCs/LAT⁽⁻⁾ TG), it was not feasible to purify TG-derived DCs in sufficient numbers to conduct systematic studies of their phenotype and function following infection with LAT⁽⁺⁾ and LAT⁽⁻⁾ virus. Therefore, the following DC phenotypic and functional studies were performed *in vitro* using bone marrow-derived DCs, which contain a mixture of both myeloid and lymphoid DCs (38,41,42,46).

LAT interferes with phenotypic maturation of DC

Immature DCs *in vitro* were left uninfected or infected with either LAT⁽⁺⁾ (*dLAT2903R*) or LAT⁽⁻⁾ (*dLAT2903*)

virus. Four hours post-infection, each DC population was stimulated with LPS for maturation, and then examined by flow cytometry for the DC maturation markers MHC class I (MHC-I), and the co-stimulatory molecules CD80 and CD86. CD40 adhesion molecule was included as a control. LPS stimulated LAT⁽⁻⁾-infected DCs induced significant maturation of DCs, with significant increases of cell surface expression of MHC-I, CD80, and CD86 co-stimulatory molecules, compared to LAT⁽⁺⁾-infected immature DCs (Fig. 2A, left panels; *p* < 0.005). LPS stimulation did not affect the surface expression of other DC markers that are unrelated to DC maturation, such as CD40 (or CD11c and CD54; not shown), suggesting that the changes in surface expression of the DC maturation markers was not due to global changes in cell surface expression. Fig. 2B shows the average mean fluorescent intensities (MFI), with each bar representing the average ± SD of four independent experiments. Together these results indicate that DC phenotypic maturation was impaired by LAT⁽⁺⁾ virus.

Next, we determined whether *in vitro* infection of immature DCs with LAT⁽⁺⁾ virus has an effect on the production




FIG. 2. Immature DCs infected with LAT⁽⁺⁾ virus had impaired phenotypic maturation and production of proinflammatory cytokines. **(A)** Representative histogram showing expression of MHC (class I), co-stimulatory molecules (CD80 and CD86), and adhesion molecule CD40, on the surface of DCs infected with LAT⁽⁺⁾ or LAT⁽⁻⁾ TG. Immature DCs were infected for 24 h with either *dLAT2903* (left panels), or *dLAT2903R* (right panels). Uninfected immature DCs were used as a negative control (thin lines in left and right panels). Four hours after infection, the infected and uninfected DCs were stimulated with LPS (1 μ g/mL). Expression of surface MHC, CD80, CD86, and CD40 were determined (solid black lines are infected LPS-matured DCs; dashed lines are uninfected LPS controls). The arrows and the gray areas indicate a significant shift of the mean fluorescence intensity to the right, indicating an upregulation of markers of maturation. **(B)** Average mean fluorescence intensity (MFI) of the expression of surface MHC, CD80, CD86, and CD40 on DCs. Each bar in panel **B** shows the average \pm SD of four independent experiments. **(C)** DCs were infected as described in **A** and **B**, and ELISA assays were performed on culture supernatants collected at 12 h post-infection. The average \pm SD of 4 independent experiments are shown (* p < 0.005).

of proinflammatory cytokines. Four hours after infection of immature DCs with either LAT⁽⁺⁾ or LAT⁽⁻⁾ viruses, they were subjected to LPS stimulation. Negative and positive controls were mock-infected (mock), and LPS-matured DCs, respectively. Production of IL-6, TNF- α , and IL-12 were quantified by sandwich ELISA, as described in the materials and methods section. DCs infected with either LAT⁽⁻⁾ or LAT⁽⁺⁾ viruses produced more IL-6, TNF- α , and IL-12 than mock-infected DCs (Fig. 2C; p < 0.005). However, LAT⁽⁺⁾-infected DCs produced significantly less IL-6, TNF- α , and IL-12 than did LAT⁽⁻⁾-infected DCs (Fig. 2C; p < 0.005). As expected, the largest amount of proinflammatory cytokines were detected in uninfected LPS-matured DCs. Thus, compared to LAT⁽⁻⁾ HSV-1-infected DCs, LAT⁽⁺⁾ HSV-1-infected DCs had decreased production of proinflammatory cytokines following stimulation with LPS.

LAT interferes with functional maturation of DCs

We further explored whether the LAT⁽⁺⁾-mediated inhibition of phenotypic maturation of DCs would translate into a functional impairment in their ability to induce HSV-specific CD8⁺ T cells. Immature bone marrow DCs were derived from H2^b mice, and infected for 4 h with LAT⁽⁻⁾ or LAT⁽⁺⁾ virus, and then incubated with LPS for an additional

16 h, as described above, to induce their maturation. Increasing numbers of infected DCs were added to a constant number (10⁵) of CD8⁺ T cells isolated from the spleens of HSV-1-infected H2^b mice 35 days post-infection. LAT⁽⁻⁾-infected DCs induced significantly more IFN- γ -producing CD8⁺ T cells than LAT⁽⁺⁾-infected DCs (p < 0.05; Fig. 3), and this occurred in a dose-dependent manner.

Latently-infected LAT⁽⁺⁾ TG have more total CD8⁺ T cells than LAT⁽⁻⁾ TG

In a pilot experiment, we compared the percentages and total numbers of T cells in mouse TG latently infected with wild-type HSV-1 (strain McKrae), that had been perfused or not perfused prior to euthanasia. No difference was found in the percentages of total CD4⁺ and CD8⁺ T cells when we compared perfused versus non-perfused mice. This was expected, since during HSV-1 latency there are few if any HSV-1-specific T cells in the circulating blood. Subsequent experiments were carried out using non-perfused mice.

We examined whether HSV-1 LAT can affect the percentages and total number of TG-resident CD4⁺ and CD8⁺ T cells. Two groups of B6 mice (n = 10) were infected ocularly with 2×10^5 pfu/eye with: (1) LAT⁽⁻⁾ virus mutant *dLAT2903* (LAT⁽⁻⁾); or with (2) its marker-rescued virus




FIG. 3. Compared to DCs infected with LAT⁽⁻⁾, immature DCs infected with LAT⁽⁺⁾ virus are inefficiently matured by LPS (as judged by their poor ability to stimulate CD8⁺ T cells). Immature bone marrow-derived DCs were infected *in vitro* for 4 h with LAT⁽⁺⁾ or LAT⁽⁻⁾ HSV-1, and incubated for 16 additional hours with 0.5 μg/mL LPS to induce maturation. The DCs were washed, and treated with mitomycin C, and the indicated numbers of DCs were incubated in duplicate for 72 h with 10⁵ autologous CD8⁺ T cells derived from spleens of wild-type McKrae-infected mice. The number of HSV-specific CD8⁺ T cells producing IFN-γ was determined by an ELISpot assay. Results show the average ±SD of two independent experiments.

dLAT2903R (LAT⁽⁺⁾) (20) (Fig. 4A). Both viruses are derived from HSV-1 strain McKrae. A third group of control mice received vehicle alone (mock-infected). We harvested TG 35 days post-infection (i.e., during latent infection), and determined the number and the percentage of CD3⁺ T cells, and of CD3⁺CD4⁺ and CD3⁺CD8⁺ T-cell populations in LAT⁽⁺⁾- and LAT⁽⁻⁾-infected TG. A significant increase in the number of CD3⁺ T cells was detected in both LAT⁽⁺⁾ TG and LAT⁽⁻⁾ TG, compared to mock-infected TG (Fig. 4B, left panels). In addition, the percentages of both CD3⁺CD4⁺ and CD3⁺CD8⁺ T-cell sub-populations were increased in latently-infected LAT⁽⁺⁾ TG and LAT⁽⁻⁾ TG compared to mock-infected TG (Fig. 4B, right panels). Interestingly, in five consecutive independent experiments (each used 10 latently-infected mice per group), the percentages of CD8⁺ T cells were significantly higher in LAT⁽⁺⁾ TG compared to LAT⁽⁻⁾ TG (Fig. 4B, right panels). Latently-infected LAT⁽⁺⁾ TG contained an approximately threefold higher percentage of CD3⁺CD8⁺ T cells compared to LAT⁽⁻⁾-infected TG. In contrast, the percentages of CD4⁺ T cells were similar in LAT⁽⁺⁾ TG and LAT⁽⁻⁾ TG (Fig. 4B, right panels). Similar results were obtained when comparing TG-resident T cells from the LAT⁽⁻⁾ virus mutant dLAT2903 (LAT⁽⁻⁾) versus WT virus McKrae (LAT⁽⁺⁾) (not shown). We previously reported

that TG from mice latently infected with LAT⁽⁺⁾ HSV-1 contain more total CD8⁺ T cells than TG from mice latently infected with LAT⁽⁻⁾ HSV-1 (47,48). The same results were obtained here. In addition, we now show that in contrast to CD8⁺ T cells, the total number of CD4⁺ T cells did not appear to vary between TG from mice latently infected with LAT⁽⁺⁾ versus LAT⁽⁻⁾ HSV-1. The average ±SD/TG of 5 independent experiments, each consisting of cells pooled from 20 TG, is shown in Fig. 4C (left panels). Based on this result, we focused on assessing the effect of LAT on the number of CD8⁺ T cells in TG.

Higher numbers of dysfunctional HSV-gB₄₉₈₋₅₀₅-specific CD8⁺ T cells are present during latency in LAT⁽⁺⁾ TG compared to LAT⁽⁻⁾ TG

To assess the effect of LAT on the DC's ability to induce TG-resident CD8⁺ T-cell function *in vivo*, groups of 40 age- and sex-matched B6 mice were ocularly infected with either LAT⁽⁺⁾ or LAT⁽⁻⁾ virus. The HSV-gB₄₉₈₋₅₀₅-epitope and B6 mice were chosen to detect HSV-1-specific CD8⁺ T cells in this study, because in this mouse strain the majority (over 50%) of CD8⁺ T cells in the periphery, as well as in latently-infected TG, are directed to this single immunodominant epitope (49–51). TG from 10 LAT⁽⁺⁾ and 10 LAT⁽⁻⁾ mice were collected 35 days post-infection (i.e., during latent infection), and TG-resident CD8⁺ T cells were isolated (Fig. 5A). The cytotoxic activity (Fig. 5B), and cytokine production (Fig. 5C), of TG-resident CD8⁺ T cells were determined following *in vitro* stimulation with DCs pulsed with HSV-1 gB₄₉₈₋₅₀₅ peptide, or DCs infected with wild-type McKrae. The HSV-1-specific CD8⁺ T-cell cytotoxic activity as determined by CD107 expression, was significantly higher in CD8⁺ T cells from TG of LAT⁽⁻⁾ latently-infected mice compared to LAT⁽⁺⁾ latently-infected mice (Fig. 5B; *p* = 0.001). Production of IFN-γ, TNF-α, and IL-12 were also higher in CD8⁺ T cells derived from mouse TG latently infected with LAT⁽⁻⁾ virus compared to LAT⁽⁺⁾ virus (Fig. 5C). These results suggest that LAT directly or indirectly interferes with DC maturation, which then leads to exhaustion of HSV-specific CD8⁺ T cells.

Discussion

This report extends our recent findings regarding the role of HSV-1 LAT in inducing CD8⁺ T-cell exhaustion in mouse TG latently infected with HSV-1 (1,2). We show here that exposure of immature DCs to wild-type HSV-1 expressing LAT (LAT⁽⁺⁾ virus) interfered with their phenotypic and functional maturation compared to LAT⁽⁻⁾ virus. *In vitro*, DCs infected with LAT⁽⁺⁾ viruses stimulated less HSV-specific CD8⁺ T cells than did DCs infected with LAT⁽⁻⁾ virus. This could logically lead to lower HSV-specific CD8⁺ T-cell responses in latently-infected TG, since DCs are present in latently-infected TG. Since functional HSV-specific CD8⁺ T cells appear to be an important immune surveillance mechanism in decreasing reactivation from latency (1,2,15–18,52–54), the relatively lower HSV-specific CD8⁺ T-cell responses observed in TG latently-infected with LAT⁽⁺⁾ virus may explain, at least in part, why LAT⁽⁺⁾ viruses have increased reactivation compared to LAT⁽⁻⁾ viruses. LAT-mediated inhibition of DC maturation would be a novel immune evasion mechanism to impair HSV-specific CD8⁺ T cells in TG. This




FIG. 4. Higher percentages of total CD8⁺ T cells were detected in LAT⁽⁺⁾ TG than in LAT⁽⁻⁾ TG during latent herpes infection. (A) Three groups of B6 mice ($n = 10$) were either left uninfected (Mock) or ocularly infected with 2×10^5 pfu/eye of: (1) LAT⁽⁻⁾ virus mutant *dLAT2903* (LAT⁽⁻⁾); or with (2) its marker-rescued virus *dLAT2903R* (LAT⁽⁺⁾) (20). Both TG were harvested from each mouse 35 days post-infection (10 mice). The 20 TG were pooled together, collagenase I treated, and the numbers and percentages of CD3⁺ T cells, CD3⁺CD4⁺ T cells, and CD3⁺CD8⁺ T cells were determined in TG cell suspensions by FACS. (B) Histogram of the numbers of CD3⁺ T cells in 20 TG. (C) The average number \pm SD of CD3⁺CD4⁺ T-cells (left panel), and CD3⁺CD8⁺ T cells (right panel) per TG on day 35 post-infection. Each bar represents five consecutive independent experiments, each consisting of cells pooled from 20 TG [$*p < 0.05$ for cell numbers in LAT⁽⁺⁾ TG versus LAT⁽⁻⁾ TG].

may be one way in which LAT helps to increase spontaneous reactivation.

In some reports (24–26,55), HSV-1 infection inhibits maturation of DCs similarly to the inhibition shown in this report for LAT⁽⁺⁾ viruses. In other reports (26,32), inhibition of DC maturation was not observed. However, since the HSV-1 strains, the mutants, the MOIs, and the durations of infection differed in these studies, direct comparisons are difficult. Using the McKrae strain of HSV-1 and its corresponding mutants, our results suggest a direct or indirect suppressive mechanism on DC maturation by LAT. In addition, unlike the virion host shutoff protein (vhs), which functions to destabilize total mRNA/proteins (55), the effect of LAT was not global. Indeed, while cell surface expression of MHC, CD80, and CD86 molecules on DCs were impaired, there was no effect on the expression of other molecules, such as CD11c or CD40. This indicates that LAT-mediated impairment of cell surface expression is specific to MHC, CD80, and CD86 molecules exclusively. Our results are in agreement with reports suggesting that HSV-1 decreases DC maturation (26,30–32,55,56). To our knowledge, the results reported here

represent the first evidence that LAT may be involved directly or indirectly in this reduced DC maturation.

We found that the expression of LAT in HSV-1-infected DCs specifically prevented production of the pro-inflammatory cytokines IL-6, IL-12, and TNF- α , following stimulation with LPS. IL-12 is critically involved in the generation of cellular immunity to HSV-1 (41,42). DCs have been identified as the major producers of IL-12 in lymph nodes, thus driving T-cell immunity towards a Th-1-type response, which is critical in protection against HSV-1 infection (41,42). The inhibitory effect of HSV-1 on IL-12 production by DCs has also been recently observed in a different experimental setting (23,32). Our results confirm and extend those findings by demonstrating that LAT enhances that ability of HSV-1 to interfere with IL-12 production in DCs. If LAT also reduces the production of proinflammatory cytokines in response to HSV-1 infection *in vivo*, it may modulate the Th-1 cell response, and help the virus reactivate by evading TG-resident CD8⁺ T-cell immunosurveillance.

We report for the first time that a small number of HSV-antigen-positive DCs are present in latently-infected TG. This




FIG. 5. Impairment of HSV-1-specific CD8 T-cell functions in TG of mice latently infected with LAT⁽⁺⁾ virus. (A) TG from B6 mice latently infected with 2×10^5 pfu/eye of either LAT⁽⁺⁾ (wild-type McKrae; $n = 10$), or LAT⁽⁻⁾ (dLAT2903 virus; $n = 10$), were removed on 35 days post-infection. (B) TG-resident CD8⁺ T cells from 20 TG per group were pooled, cell suspensions were prepared, and cells were stimulated with DCs pulsed with HSV-1 gB₄₉₈₋₅₀₅ peptide. Then, 72 h later, the stimulated cells were triple-stained with anti-mouse CD8 mAb, HSV-gB₄₉₈₋₅₀₅/tetramers, and anti-mouse CD107^{a/b} mAb. The average number of HSV-gB₄₉₈₋₅₀₅-epitope-specific CD8⁺ T cells expressing CD107^{a/b} were determined by FACS. The average \pm SD of two independent experiments, each done in duplicate, is shown. (C) A portion of the pooled CD8⁺ T cells from the experiment shown in B were removed prior to *in vitro* stimulation. CD8⁺ T cells were re-stimulated *in vitro* with DCs infected with HSV-1 (DC-HSV), incubation with medium alone (negative control DCs without antigen, None), or stimulated with Con A (positive control, Con-A). The amount of IFN- γ , TNF- α , and IL-12 was determined by ELISA 72 h after incubation. The results shown are the average \pm SD of two independent experiments, each done in duplicate. The asterisks indicate that the amount of each indicated cytokine was significantly different in LAT⁽⁺⁾ versus LAT⁽⁻⁾ cells.

does not imply that TG-resident DCs were actually infected with HSV-1 or harbored latent virus. When and where the DCs acquired HSV-1 Ags, either through HSV-1 infection of DCs, through cross-presentation mechanisms by which DCs acquired Ags from necrotic or apoptotic HSV-1-infected neurons, or through other mechanisms, are important questions for future studies. Kinetic studies will be required to determine when and where TG-resident DCs become positive for HSV-1 Ag. It will also be of interest to determine if the HSV-1 Ag-positive DCs acquired virus or Ag at the periphery and then migrated to the TG, or whether these DCs were resident in the TG and acquired virus or Ag within the TG. In the latter case, it will be of interest to determine if the HSV-1 Ag-positive DCs acquired HSV-1 virus or Ag prior to or after establishment of latency. In addition, since only a very small number of HSV-antigen-positive DCs (~6-15) appear to be present in latently-infected TG, sorting these cells for functional analysis, co-localization studies of H2^b and herpes antigens, or RT-PCR was not feasible.

CD8⁺ T cells appear to be important in monitoring HSV-1 reactivations (13,17). During HSV-1 neuronal latency in TG of mice and humans, some neurons are surrounded by CD8⁺ T cells (52,57-61). Since CD8⁺ T cells are presumably attracted to these neurons by viral Ags, it is assumed that the neurons surrounded by CD8⁺ T cells are those in which the virus has initiated the early stages of reactivation from la-

tency. In mice, experimental reactivation of HSV-1 from latency is typically accomplished by explanting TG into tissue culture media for up to 14 days, and testing for the appearance of infectious (i.e., reactivated) virus. In this TG explant-induced reactivation model, depleting CD8⁺ T cells with specific mAbs leads to the detection of more reactivated virus (57). Conversely, the addition of exogenous CD8⁺ T cells reduces detection of reactivated virus (17,62). Thus, with wild-type HSV-1, CD8⁺ T cells in the TG are apparently able to reduce the detection of infectious reactivated virus.

We recently showed that during latency the function of HSV-specific CD8⁺ T cells is partially impaired in the TG of mice that had been ocularly infected with LAT⁽⁺⁾ HSV-1 compared to LAT⁽⁻⁾ HSV-1 (McKrae strain) (1,2). In mice latently infected with the KOS strain of HSV-1 via flank scarification, Mackay *et al.*, more recently showed that HSV-specific CD8⁺ T cells derived from sensory dorsal root ganglia (DRG) do retain the functional ability to respond to local challenge with wild-type virus (14). However, that elegant study did not compare CD8⁺ T-cell function in the DRG or TG of mice latently infected with LAT⁽⁺⁾ versus LAT⁽⁻⁾ HSV-1. The finding in the present study that compared to LAT⁽⁻⁾ HSV-1, LAT⁽⁺⁾ HSV-1 interferes with DC maturation, suggests a mechanism by which LAT may reduce CD8⁺ T-cell function in the TG of HSV-1-infected mice. In other systems it is well known that a high-sustained Ag

load can lead to CD8⁺ T-cell exhaustion (63–66). However, during latency in mouse TGs, very few neurons have detectable viral Ag by immunostaining (1,2,67,68). The amount of latency and detectable viral Ag in sensory neurons of TG from mice latently infected with LAT⁽⁻⁾ virus is even lower than with LAT⁽⁺⁾ virus (1,2). Consistent with this, we found that there were more HSV-1 Ag-positive DCs in the TG of CD11c/eYFP transgenic mice latently infected with LAT⁽⁺⁾ virus, compared to LAT⁽⁻⁾ virus. This is another mechanism by which LAT may increase CD8⁺ T-cell exhaustion in latently infected TG. Thus, even though CD8⁺ T cells are much more sensitive to Ag than the antibodies used for immunostaining, the very low un-sustained Ag level that appears to be the situation in TG-resident DCs may result in the exhaustion of CD8⁺ T cells. Thus, it seems that the CD8⁺ T-cell exhaustion could be due to the viral Ag load from DCs, unless additional factors contribute to immune stimulation. For example, TG-resident HSV-specific CD8⁺ T cells could have a higher functional avidity (ability to respond to low epitope density) than their counterparts in the periphery (15). Alternatively, CD8⁺ T-cell exhaustion may suggest that there

is a lot more viral Ag present in the TG of mice latently infected with LAT⁽⁺⁾ virus than has previously been thought, or that there is a lot of undetected viral reactivation in the TG of mice latently infected with LAT⁽⁺⁾ viruses.

The consequences of LAT interfering with DC maturation, and LAT resulting in increased DC Ag load, may both lead to decreased CD8 T-cell function. This may have implications for the immune evasion of the virus and its reactivation in latently infected TG. As illustrated in Fig. 6, if HSV-1-specific CD8 T cells in the TG help prevent initiation of viral reactivation, then LAT's ability to interfere with DC maturation may be involved in LAT's ability to increase viral reactivation. Thus, LAT's ability to cause significantly more phenotypic and functional exhaustion of CD8 T cells in latently infected TG (1,2), combined with LAT's ability to interfere with DC maturation, may constitute a significant immune-evasion mechanism, which results in increased viral reactivation from latency.

Although LAT does not appear to make any abundant protein, it does encode 2 small RNAs with anti-apoptosis activity (69), and 8 miRNAs (70,71). One or more of these RNAs




FIG. 6. Proposed model explaining the immune evasion mechanisms whereby the HSV-1 LAT interferes with DC maturation and promotes dysfunctional HSV-specific CD8⁺ T cells, resulting in more virus reactivation (see text for details). Immature DCs (red) exert sentinel functions at peripheral sites, including the latently-infected TG, and are highly efficient in antigen capture, but poor in stimulating T cells. In contrast, mature DCs (peach color), are highly efficient in presenting processed antigen to naive CD8⁺ T cells, and promote expansion of memory CD8⁺ T cells. While similar numbers of DCs exist in LAT⁽⁺⁾ and LAT⁽⁻⁾ TG, unlike DCs infected with LAT⁽⁻⁾ virus, DCs infected with LAT⁽⁺⁾ viruses have less cell surface expression of MHC class I and the co-stimulatory molecules CD80 and CD86, along with impaired production of IL-6, IL-12, and TNF- α . Consequently, LAT⁽⁺⁾ immature DCs, but not LAT⁽⁻⁾ DCs, are unable to stimulate HSV-specific CD8⁺ T-cell function. Thus CD8⁺ T cells in the LAT⁽⁺⁾ TG have less cytotoxic activity (CTL killing), and cytokine (IFN- γ) production, which would decrease virus reactivation from sensory neurons. These results suggest a novel immune-evasion mechanism whereby HSV-1 LAT interferes with DC maturation to indirectly escape immunosurveillance by TG-resident CD8⁺ T cells, and consequently increases viral reactivation. Color images available online at www.liebertonline.com/vim

may be involved in how LAT interferes with DC maturation and CD8 T-cell exhaustion. However, investigation of these possibilities is beyond the scope of the present study.

In summary, we have shown here, for the first time, that LAT interferes with phenotypic and functional maturation of DCs. Either or both of these LAT functions may represent a LAT-mediated immune-evasion mechanism, whereby LAT indirectly leads to HSV-specific CD8⁺ T-cell exhaustion in latently infected TG. This would represent a LAT function, in addition to its ability to block apoptosis (19), that may play an important role in increasing reactivation of HSV-1.

Acknowledgments

This work was supported by Public Health Service NIH grants EY14017, EY14900, and EY019896 to L.B.M., EY013191 and EY018171 to S.L.W., The Discovery Eye Foundation, and a Research to Prevent Blindness Challenge grant. L.B.M. is an RPB Award Investigator. The authors would like to thank Dr. Douglas McAlester (ViroStat) for kindly sharing herpes monoclonal antibodies, and Dr. James V. Jester and Dr. Donald Brown for assistance with the confocal microscopy studies. We also would like to thank Dr. Alison Deckhut Augustine and Amy K. Stout from the NIH Tetramer Facility for providing the tetramers used in this study.

Author Disclosure Statement

No competing financial interests exist.

References

- Chentoufi AA, Kritzer E, Tran MV, et al.: The herpes simplex virus 1 latency-associated transcript promotes functional exhaustion of virus-specific CD8⁺ T cells in latently infected trigeminal ganglia: a novel immune evasion mechanism. *J Virol* 2011;85:9127–9138.
- Allen SJ, Hamrah P, Gate D, et al.: The role of LAT in increased CD8⁺ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. *J Virol* 2011;85:4184–4197.
- Goldwich A, Prechtel AT, Muhl-Zurbes P, et al.: Herpes simplex virus type 1 (HSV-1) replicates in mature dendritic cells but can only be transferred in a cell-cell contact-dependent manner. *J Leukoc Biol* 2011;89:973–979.
- Conrady CD, Thapa M, Wuest T, and Carr DJ: Loss of mandibular lymph node integrity is associated with an increase in sensitivity to HSV-1 infection in CD118-deficient mice. *J Immunol* 2009;182:3678–3687.
- Chentoufi AA, and BenMohamed L: Future viral vectors for the delivery of asymptomatic herpes epitope-based immunotherapeutic vaccines. *Future Virol* 2010;5:525–528.
- Chentoufi AA, Dasgupta G, Christensen ND, et al.: A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8⁺ T cell epitope-based vaccines against ocular herpes. *J Immunol* 2010;184:2561–2571.
- Chentoufi AA, Dasgupta G, Nesburn AB, et al.: Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization. *Clin Vaccine Immunol* 2010;17:342–353.
- Jiang X, Chentoufi AA, Hsiang C, et al.: The herpes simplex virus type 1 latency associated transcript (LAT) can protect neuronal derived C1300 and Neuro2A cells from Granzyme B induced apoptosis and CD8 T-cell killing. *J Virol* 2010;85:2325–2332.
- Jiang X, Chentoufi AA, Hsiang C, et al.: The herpes simplex virus type 1 latency-associated transcript can protect neuron-derived C1300 and Neuro2A cells from granzyme B-induced apoptosis and CD8 T-cell killing. *J Virol* 2011;85:2325–2332.
- Rubbo PA, Tuailon E, Nagot N, et al.: HIV-1 infection impairs HSV-specific CD4⁺ and CD8⁺ T cell response by reducing Th1 cytokines and CCR5 ligand secretion. *AIDS* 2011 [In press].
- Hill A, Jugovic P, York I, et al.: Herpes simplex virus turns off the TAP to evade host immunity. *Nature* 1995;375:411–415.
- Tomazin R, van Schoot NE, Goldsmith K, et al.: Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. *J Virol* 1998;72:2560–2563.
- van Lint AL, Kleinert L, Clarke SR, et al.: Latent infection with herpes simplex virus is associated with ongoing CD8⁺ T-cell stimulation by parenchymal cells within sensory ganglia. *J Virol* 2005;79:14843–14851.
- Mackay LK, Wakim L, van Vliet CJ, et al.: Maintenance of T cell function in the face of chronic antigen stimulation and repeated reactivation for a latent virus infection. *J Immunol* 2012.
- Frank GM, Lepisto AJ, Freeman ML, et al.: Early CD4(+) T cell help prevents partial CD8(+) T cell exhaustion and promotes maintenance of Herpes Simplex Virus 1 latency. *J Immunol* 2010;184:277–286.
- Sheridan BS, Khanna KM, Frank Gm, and Hendricks RL: Latent virus influences the generation and maintenance of CD8⁺ T cell memory. *J Immunol* 2006;177:8356–8364.
- Khanna KM, Bonneau RH, Kinchington PR, and Hendricks RL: Herpes simplex virus-specific memory CD8⁺ T cells are selectively activated and retained in latently infected sensory ganglia. *Immunity* 2003;18:593–603.
- Neumann J, Eis-Hubinger AM, and Koch N: Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion. *J Immunol* 2003;171:3075–3083.
- Peng GC, Jones C, Ciacci-Zanella J, et al.: Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. *Science* 2000;287:1500–1503.
- Peng W, Henderson G, Inman M, et al.: The locus encompassing the latency-associated transcript of herpes simplex virus type 1 interferes with and delays interferon expression in productively infected neuroblastoma cells and trigeminal ganglia of acutely infected mice. *J Virol* 2005;79:6162–6171.
- Agrawal A, Lingappa J, Leppla SH, et al.: Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. *Nature* 2003;424:329–334.
- Banchereau J, and Steinman RM: Dendritic cells and the control of immunity. *Nature* 1998;392:245–252.
- Cella M, Salio M, Sakakibara Y, et al.: Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. *J Exp Med* 1999;189:821–829.
- Mikloska Z, Bosnjak L, and Cunningham AL: Immature monocyte-derived dendritic cells are productively infected with herpes simplex virus type 1. *J Virol* 2001;75:5958–5964.
- Mikloska Z, and Cunningham AL: Alpha and gamma interferons inhibit herpes simplex virus type 1 infection and spread in epidermal cells after axonal transmission. *J Virol* 2001;75:11821–11826.
- Pollara G, Speidel K, Samady L, et al.: Herpes simplex virus infection of dendritic cells: balance among activation, inhibition, and immunity. *J Infect Dis* 2003;187:165–178.

27. Steinman RM: The dendritic cell system and its role in immunogenicity. *Annu Rev Immunol* 1991;9:271–296.
28. Probst HC, McCoy K, Okazaki T, et al.: Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. *Nat Immunol* 2005;6:280–286.
29. Allen SJ, Mott KR, Chentoufi AA, et al.: CD11c controls Herpes Simplex Virus 1 responses to limit virus replication during primary infection. *J Virol* 2011;85:9945–9955.
30. Kruse CA, Lamb C, Hogan S, et al.: Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms. *Cancer Gene Ther* 2000;7:118–127.
31. Kruse M, Rosorius O, Kratzer F, et al.: Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. *J Virol* 2000;74:7127–7136.
32. Salio M, Cella M, Suter M, and Lanzavecchia A: Inhibition of dendritic cell maturation by herpes simplex virus. *Eur J Immunol* 1999;29:3245–3253.
33. Jin H, Ma Y, Prabhakar BS, et al.: The gamma 1 34.5 protein of herpes simplex virus 1 is required to interfere with dendritic cell maturation during productive infection. *J Virol* 2009;83:4984–4994.
34. Schuster P, Donhauser N, Pritschet K, et al.: Co-ordinated regulation of plasmacytoid dendritic cell surface receptors upon stimulation with herpes simplex virus type 1. *Immunology* 2010;129:234–247.
35. Kittan NA, Bergua A, Haupt S, et al.: Impaired plasmacytoid dendritic cell innate immune responses in patients with herpes virus-associated acute retinal necrosis. *J Immunol* 2007;179:4219–4230.
36. Gottfried-Blackmore A, Kaunzner UW, Idoyaga J, et al.: Acute *in vivo* exposure to interferon-gamma enables resident brain dendritic cells to become effective antigen presenting cells. *Proc Natl Acad Sci USA* 2009;106:20918–20923.
37. Bulloch K, Miller MM, Gal-Toth J, et al.: CD11c/EYFP transgene illuminates a discrete network of dendritic cells within the embryonic, neonatal, adult, and injured mouse brain. *J Comp Neurol* 2008;508:687–710.
38. Bettahi I, Nesburn AB, Yoon S, et al.: Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. *Invest Ophthalmol Vis Sci* 2007;48:4643–4653.
39. Zhang X, Issagholian A, Berg EA, et al.: Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. *J Virol* 2005;79:15289–15301.
40. Chentoufi AA, Zhang X, Lamberth K, et al.: HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. *J Immunol* 2008;180:426–437.
41. BenMohamed L, Bertrand G, McNamara CD, et al.: Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. *J Virol* 2003;77:9463–9473.
42. BenMohamed L, Belkaid Y, Loing E, et al.: Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. *Eur J Immunol* 2002;32:2274–2281.
43. Zhang X, Chentoufi AA, Dasgupta G, et al.: A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. *Mucosal Immunol* 2009;2:129–143.
44. Jin L, Perng GC, Brick DJ, et al.: Methods for detecting the HSV-1 LAT anti-apoptosis activity in virus infected tissue culture cells. *J Virol Methods* 2004;118:9–13.
45. Perng GC, Mott KR, Osorio N, et al.: Herpes simplex virus type 1 mutants containing the KOS strain ICP34.5 gene in place of the McKrae ICP34.5 gene have McKrae-like spontaneous reactivation but non-McKrae-like virulence. *J Gen Virol* 2002;83:2933–2942.
46. Zhu X, Ramos TV, Gras-Masse H, et al.: Lipopeptide epitopes extended by ne-palmitoyl lysine moiety increases uptake and maturation of dendritic cell through a toll-like receptor 2 pathway and triggers a Th1-dependent protective immunity. *Eur J Immunol* 2004;34:1142–1149.
47. Allen SJ, Hamrah P, Gate D, et al.: The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. *J Virol* 2011;85:4184–4197.
48. Chentoufi AA, Kritzer E, Tran MV, et al.: The herpes simplex virus 1 latency-associated transcript promotes functional exhaustion of virus-specific CD8+ T cells in latently infected trigeminal ganglia: a novel immune evasion mechanism. *J Virol* 2011;85:9127–9138.
49. Blaney JE Jr, Nobusawa E, Brehm MA, et al.: Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. *J Virol* 1998;72:9567–9574.
50. Bonneau RH, Salvucci LA, Johnson DC, and Tevethia SS: Epitope specificity of H-2Kb-restricted, HSV-1-, and HSV-2-cross-reactive cytotoxic T lymphocyte clones. *Virology* 1993;195:62–70.
51. Cose SC, Kelly JM, and Carbone FR: Characterization of diverse primary herpes simplex virus type 1 gB-specific cytotoxic T-cell response showing a preferential V beta bias. *J Virol* 1995;69:5849–5852.
52. Verjans GM, Hintzen RQ, van Dun JM, et al.: Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. *Proc Natl Acad Sci USA* 2007;104:3496–3501.
53. Theil D, Arbusow V, Derfuss T, et al.: Prevalence of HSV-1 LAT in human trigeminal, geniculate, and vestibular ganglia and its implication for cranial nerve syndromes. *Brain Pathol* 2001;11:408–413.
54. Derfuss T, Segerer S, Herberger S, et al.: Presence of HSV-1 immediate early genes and clonally expanded T-cells with a memory effector phenotype in human trigeminal ganglia. *Brain Pathol* 2007;17:389–398.
55. Samady L, Costigliola E, MacCormac L, et al.: Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy. *J Virol* 2003;77:3768–3776.
56. Schon E, Harandi AM, Nordstrom I, et al.: Dendritic cell vaccination protects mice against lethality caused by genital herpes simplex virus type 2 infection. *J Reprod Immunol* 2001;50:87–104.
57. Knickelbein JE, Khanna KM, Yee MB, et al.: Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. *Science* 2008;322:268–271.
58. Theil D, Derfuss T, Paripovic I, et al.: Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. *Am J Pathol* 2003;163:2179–2184.
59. Hufner K, Derfuss T, Herberger S, et al.: Latency of alpha-herpes viruses is accompanied by a chronic inflammation in

- human trigeminal ganglia but not in dorsal root ganglia. *J Neuropathol Exp Neurol* 2006;65:1022–1030.
60. Simmons A, and Tscharke DX: Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. *J Exp Med* 1992;175:1337–1344.
61. Shimeld C, Whiteland JL, Nicholls SM, et al.: Immune cell infiltration and persistence in the mouse trigeminal ganglion after infection of the cornea with herpes simplex virus type 1. *J Neuroimmunol* 1995;61:7–16.
62. Hoshino Y, Pesnicak L, Cohen JI, and Straus SE: Rates of reactivation of latent herpes simplex virus from mouse trigeminal ganglia *ex vivo* correlate directly with viral load and inversely with number of infiltrating CD8+ T cells. *J Virol* 2007;81:8157–8164.
63. Barber DL, Wherry EJ, Masopust D, et al.: Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature* 2006;439:682–687.
64. Jin HT, Anderson AC, Tan WG, et al.: Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. *Proc Natl Acad Sci USA* 2010;107:14733–14738.
65. Ha SJ, Mueller SN, Wherry EJ, et al.: Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. *J Exp Med* 2008;205:543–555.
66. Wherry EJ, Ha SJ, Kaech SN, et al.: Molecular signature of CD8+ T cell exhaustion during chronic viral infection. *Immunity* 2007;27:670–684.
67. Ellison AR, Yang L, Voytek C, and Margolis TP: Establishment of latent herpes simplex virus type 1 infection in resistant, sensitive, and immunodeficient mouse strains. *Virology* 2000;268:17–28.
68. Feldman LT, Ellison AR, Voytek CC, et al.: Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. *Proc Natl Acad Sci USA* 2002;99:978–983.
69. Peng W, Vitvitskaia O, Carpenter D, et al.: Identification of two small RNAs within the first 1.5-kb of the herpes simplex virus type 1-encoded latency-associated transcript. *J Neurovirol* 2008;14:41–52.
70. Umbach JL, Wang K, Tang S, et al.: Identification of viral microRNAs expressed in human sacral ganglia latently infected with herpes simplex virus 2. *J Virol* 2010;84:1189–1192.
71. Umbach JL, Kramer MF, Jurak I, et al.: MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. *Nature* 2008;454:780–783.

Address correspondence to:

Dr. Lbachir BenMohamed
Laboratory of Cellular and Molecular Immunology
The Gavin Herbert Eye Institute
Hewitt Hall, Room 232
843 Health Sciences Road
Irvine, CA 92697-4390

E-mail: Lbenmoha@uci.edu

Dr. Chentoufi
Pathology and Clinical Laboratory Medicine
Department of Immunology
King Fahad Medical City
Riyadh
Kingdom of Saudi Arabia

Received December 5, 2011; accepted February 6, 2012.